[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"long-term-follow-up\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:long-term-follow-up":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,68,113],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100617073","evaluation-of-acute-and-chronic-nephrotoxicity-in-acute-lymphatic-leukemia-patients-using-ultrasound-localization-microscopy-100617073",false,"NCT07313878","Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization Microscopy","HEALED","Inclusion Criteria:\n\n* Diagnosed acute lymphatic leukemia\n* From 3 years to \\\u003C 18 years\n* completed oncological treatment or treatment day \\\u003C 50 according to therapy protocol and no administration of CPM before first examination.\n\nExclusion Criteria:\n\n* Known allergic disposition to SonoVue \u002F other contrast agents\n* Tattoo in the area of the examination field\n* Pregnancy\n* Breastfeeding mothers\n* Contraindication for the use of Sonovue\n* Critical condition\n* Known clinically evident renal impairment","ALL","3 Years","17 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","With increasing survival rates in pediatric oncology, reports of long-term side effects persisting decades after treatment are also rising. Clinically evident nephropathies occur in about 5.5% of survivors more than five years after therapy. Chemotherapeutic agents such as ifosfamide, cisplatin, and carboplatin, as well as kidney-directed treatments like radiation, surgery, or stem cell transplantation, increase this risk. Acute kidney injury has also been described in association with cyclophosphamide and high-dose methotrexate, which are used in the treatment of acute lymphoblastic leukemia (ALL). Studies show a high prevalence of albuminuria (around 14.5% of childhood cancer survivors), an early marker of kidney damage, while standard parameters like creatinine often become abnormal only at later stages.\n\nLeukemia survivors suffer from vascular late effects caused by persistent endothelial damage triggered by cancer therapies such as anthracyclines, cyclophosphamide, and asparaginase, which increase inflammation and thrombosis risk. These vascular changes may also contribute to kidney injury.\n\nULM is a high-resolution ultrasound technique that uses microbubbles to visualize the microvasculature and resolve dynamic blood flow changes with a resolution beyond the diffraction limit. ULM is independent of kidney or liver function, has been applied in various organs, and was recently used for the first time to visualize glomeruli-the smallest functional units of the kidney-in humans. This method enables early detection of glomerular injury as a consequence of vascular damage, even before albuminuria appears, potentially allowing earlier adaptation of follow-up and initiation of treatment.\n\nThis pilot project focuses on survivors of ALL, as they are the largest and best studied pediatric cancer patient group also regarding late effects and, therefore, a sufficient number of individuals can be expected for his monocentric approach. Vascular functional impairment of the kidney could be detected at an early stage and the follow-up structures and measures such as the early use of nephroprotective drugs could be adapted.",[27,28],"Acute Lymphoblastic Leukaemias (ALL)","Long Term Follow-Up","RECRUITING","2025-12-22",{"date":32,"type":33},"2026-01-02","ACTUAL",{"date":35,"type":33},"2025-11-19",{"date":37,"type":21},"2026-11-30",{"name":39,"class":40},"University of Erlangen-Nürnberg Medical School","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100411610","monitoring-the-weight-evolution-using-a-connected-scale-100411610","NCT04639778","Monitoring the Weight Evolution Using a Connected Scale","Evaluation of a Personalized Care Path After Bariatric Surgery Based on Monitoring the Weight Evolution Using a Connected Scale","TELEBARIA","Inclusion Criteria:\n\nPatients aged\\> = at 18 years old Patients who have benefited from a Roux-en-Y Gastric By-Pass or Sleeve Gastrectomy bariatric surgery 2 years ago Preoperative Body Mass Index between 35 kg\u002Fm2 and 59 kg\u002Fm2 Access to the wired network at home. Social insured patient Patient who signed the informed consent\n\nExclusion Criteria:\n\nLack of autonomy for the use of remote monitoring equipment or psychological or psychiatric disorders making it difficult to optimally use the remote monitoring equipment\n\nAdministrative reasons: inability to receive informed consent information, inability to participate in the entire study, lack of social security coverage, refusal to sign consent, patient under guardianship or justice system.","18 Years",{"count":52,"type":21},390,[24],"Current guideline recommend yearly multidisciplinary postoperative follow-up after bariatric surgery. However, practices remain very heterogeneous, and only a fraction of patients are still follow-up beyond two years after the operation.\n\nThis study will assess a new care pathway in which the patients are follow-up according to the weight evolution measured by the patient using a connected scale.",[56,28,57],"Bariatric Surgery","Weight Regain","2025-12-17",{"date":60,"type":33},"2025-12-24",{"date":62,"type":33},"2021-03-25",{"date":64,"type":21},"2026-12",{"name":66,"class":40},"University Hospital, Lille",2,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":79,"conditions":80,"keywords":94,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":41},"100615334","long-term-follow-up-of-the-offspring-born-to-mothers-with-a-solid-organ-transplant-transplantlines-next-generation-100615334","NCT07291258","Long-term Follow-up of the Offspring Born to Mothers With a Solid Organ Transplant, Transplantlines Next Generation","Long-term Follow-up of the Offspring Born to Mothers With a Solid Organ Transplant","Inclusion Criteria:\n\n* Mother with a KTx, LiTx, PTx (including pancreas islet transplantation), HTx or LuTx before pregnancy (including mothers with multiple transplantation types)\n* Age ≥16 years for offspring born to mother with a KTx or LiTx\n\nExclusion Criteria:\n\n* No informed consent\n* Non Dutch or English speaking",true,{"count":77,"type":21},200,"OBSERVATIONAL","Background Pregnancy after all types of solid organ transplantation (SOT) is possible, although these have higher risk of pregnancy complications for mother and child, such as preeclampsia and preterm birth. Thus, the development of the unborn child seems to be affected by the transplant and its consequences such as the immunosuppressive medication use. Worldwide data regarding follow-up after birth is scarce. The very limited existing data existing only in young children are reassuring. However, the investigators hypothesize that there are health risks for the children. Given the side effects of the immunosuppressive medication on patients and limited knowledge from animal studies, the investigators particularly expect cardiovascular effects such as hypertension and kidney damage. These develop over a long time-period and lead late to symptoms.\n\nAims Aim of this study is to gain more insight into the overall health of offspring born after SOT. Primary aim is to assess the cardiovascular health and the presence of kidney disease, and compare these with reference values from the general population or birth cohorts. Secondary aims are the immunological status including the microbiome of the child given the maternal immunosuppressive medication use, and the overall development of the offspring, including qualitative research regarding the quality of life. Third aim is to assess if there are differences in health between offspring born to mothers with a kidney, liver, pancreas (including pancreas islet), heart and lung transplantation (KTx, LiTx, PTx, HTx, LuTx resp.). The investigators also want to establish a biobank for later follow-up research.\n\nStudy design This will be a cross-sectional monocenter cohort study. All offspring ≥16 years of age born after KTx or LiTx and all offspring born at any age after PTx, HTx and LuTx in the Netherlands will be eligible for inclusion. The investigators estimate that there will be about 150(-220) participants. Before the study visit, participants will be asked to complete a questionnaire. Participants will be invited for a one-time study visit consisting of physical tests (including ultrasound of the kidneys and a 24-hour ambulatory blood pressure measurement) and biological sample (urine, blood and feces) collection, including sample collection for biobanking. Information about the growth and development of the offspring and, if present, diseases and medication use will be collected from the medical files of the general practitioner and pharmacy (LSP) and from data from the youth healthcare check-ups. As a control group pseudoanonymized data from the Lifelines cohort will be used.\n\nDeliverables To the best of our knowledge, this will be the first study worldwide that will gather and analyze detailed information about the cardiovascular, kidney and immunological health at a later age (≥16 years) in the offspring born to mothers after KTx, LiTx, PTx, HTx and LuTx. This information will be important for the preconceptional counseling of families with a pregnancy wish after transplantation and thereby contribute to the health of women with a SOT. Next to that, find adverse effects of the pregnancy after transplantation on the offspring are found, the investigators expect there will be modifiable factors and\u002For early screening\u002Finterventions that can reduce these risks and thereby contribute to the health of the offspring.",[81,82,83,84,85,86,87,88,89,90,91,92,93],"Solid Organ Transplantation","Pregnancy","Long-term Follow-up","Kidney Transplant","Liver Transplant","Pancreas Transplant","Heart Transplantation","Lung Transplantation","Offspring, Adult","Children","Cardiovascular Abnormalities","Kidney Disease","Quality of Life",[95,82,96,97,98,99,100,101,102,103],"Solid organ transplantation","Offspring","Long-term follow-up","kidney transplantation","liver transplantation","pancreas transplantation","pancreas islet transplantation","Heart transplantation","lung transplantation","2025-12-04",{"date":106,"type":33},"2025-12-18",{"date":108,"type":33},"2025-10-15",{"date":110,"type":21},"2028-06",{"name":112,"class":40},"University Medical Center Groningen",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":120,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":137},"100537377","long-term-follow-up-study-for-subjects-with-chb-previously-treated-with-imdusiran-ab729-100537377","NCT06277037","Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)","A Long-Term Follow-up Study for Subjects With Chronic Hepatitis B Previously Treated With Imdusiran (AB-729)","Key Inclusion Criteria:\n\n* Have participated in a prior imdusiran clinical trial,\n* Have discontinued NA therapy in that trial and remain off NA therapy,\n* Have completed less than 3 years of follow-up visits after NA discontinuation in the parent study.\n* Have the ability to review and provide signed informed consent which includes compliance with all protocol-specified visit schedules and requirements.\n\nExclusion Criteria:\n\n* Not applicable","20 Years","70 Years",{"count":123,"type":21},50,"This is a long term follow-up study for chronic hepatitis B (CHB) subjects who have received imdusiran treatment in a prior clinical trial, stopped NA therapy during that trial, and remain off therapy. Subjects may enroll after completing the end of study visit (baseline visit within 12 weeks ± 1 week from the end of study \\[EOS\\] visit) from their imdusiran clinical trial (the \"parent study\"). No interventions will be performed in this study other than blood sample collections, review of current medications, and reporting of any adverse events related to study procedures or NA therapy if restarted. Study participation will be for approximately 2 years (to complete a total of at least 3 years of follow-up while off NA therapy, inclusive of parent study participation).",[126],"Long Term Follow-up","2024-11-25",{"date":129,"type":33},"2024-11-27",{"date":131,"type":33},"2024-07-11",{"date":133,"type":21},"2029-10-30",{"name":135,"class":136},"Arbutus Biopharma Corporation","INDUSTRY",18]